Tags

Type your tag names separated by a space and hit enter

A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis.
Pediatr Allergy Immunol. 2012 Nov; 23(7):667-73.PA

Abstract

BACKGROUND

There have been considerable disagreements regarding the therapeutic effects of probiotics in atopic dermatitis (AD). We performed this study to examine whether the oral administration of Lactobacillus plantarum CJLP133 improves pediatric AD.

METHODS

In a randomized, double-blind, placebo-controlled study, either L. plantarum CJLP133 at a dosage of 0.5 × 10(10) colony-forming units or placebo in children aged 12 months to 13 yr was given twice a day for 12 wk. SCOring of Atopic Dermatitis (SCORAD) scores, eosinophil counts, serum total IgE, and cytokines were evaluated.

RESULTS

Forty-four of 58 patients in the probiotic group and 39 of 60 patients in the placebo group completed the study. The SCORAD score at week 14 was lower in the probiotic group than in the placebo group (p = 0.044). The mean change in the SCORAD score from weeks 2 to 14 was 9.1 in the probiotic group, which was greater than the mean change of 1.8 in the placebo group (p = 0.004). No statistical differences in the total use of topical corticosteroids were found between two groups (p = 0.815). In the probiotic group, the total eosinophil count was significantly lower at the end of the intervention compared to the baseline measurements (p = 0.023). Logarithmic IFN-γ and IL-4 were significantly decreased by the end of the intervention compared to baseline measurements in the probiotic group (p < 0.001 and 0.049).

CONCLUSIONS

Our results suggest that supplementation with probiotic L. plantarum CJLP133 is beneficial in the treatment of pediatric AD.

Authors+Show Affiliations

Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23050557

Citation

Han, Youngshin, et al. "A Randomized Trial of Lactobacillus Plantarum CJLP133 for the Treatment of Atopic Dermatitis." Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology, vol. 23, no. 7, 2012, pp. 667-73.
Han Y, Kim B, Ban J, et al. A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatr Allergy Immunol. 2012;23(7):667-73.
Han, Y., Kim, B., Ban, J., Lee, J., Kim, B. J., Choi, B. S., Hwang, S., Ahn, K., & Kim, J. (2012). A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology, 23(7), 667-73. https://doi.org/10.1111/pai.12010
Han Y, et al. A Randomized Trial of Lactobacillus Plantarum CJLP133 for the Treatment of Atopic Dermatitis. Pediatr Allergy Immunol. 2012;23(7):667-73. PubMed PMID: 23050557.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. AU - Han,Youngshin, AU - Kim,Bongjoon, AU - Ban,Jeongsook, AU - Lee,Jeongok, AU - Kim,Beom Joon, AU - Choi,Byung Sun, AU - Hwang,Sehee, AU - Ahn,Kangmo, AU - Kim,Jihyun, Y1 - 2012/10/11/ PY - 2012/08/30/accepted PY - 2012/10/12/entrez PY - 2012/10/12/pubmed PY - 2013/4/23/medline SP - 667 EP - 73 JF - Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology JO - Pediatr Allergy Immunol VL - 23 IS - 7 N2 - BACKGROUND: There have been considerable disagreements regarding the therapeutic effects of probiotics in atopic dermatitis (AD). We performed this study to examine whether the oral administration of Lactobacillus plantarum CJLP133 improves pediatric AD. METHODS: In a randomized, double-blind, placebo-controlled study, either L. plantarum CJLP133 at a dosage of 0.5 × 10(10) colony-forming units or placebo in children aged 12 months to 13 yr was given twice a day for 12 wk. SCOring of Atopic Dermatitis (SCORAD) scores, eosinophil counts, serum total IgE, and cytokines were evaluated. RESULTS: Forty-four of 58 patients in the probiotic group and 39 of 60 patients in the placebo group completed the study. The SCORAD score at week 14 was lower in the probiotic group than in the placebo group (p = 0.044). The mean change in the SCORAD score from weeks 2 to 14 was 9.1 in the probiotic group, which was greater than the mean change of 1.8 in the placebo group (p = 0.004). No statistical differences in the total use of topical corticosteroids were found between two groups (p = 0.815). In the probiotic group, the total eosinophil count was significantly lower at the end of the intervention compared to the baseline measurements (p = 0.023). Logarithmic IFN-γ and IL-4 were significantly decreased by the end of the intervention compared to baseline measurements in the probiotic group (p < 0.001 and 0.049). CONCLUSIONS: Our results suggest that supplementation with probiotic L. plantarum CJLP133 is beneficial in the treatment of pediatric AD. SN - 1399-3038 UR - https://www.unboundmedicine.com/medline/citation/23050557/A_randomized_trial_of_Lactobacillus_plantarum_CJLP133_for_the_treatment_of_atopic_dermatitis_ L2 - https://doi.org/10.1111/pai.12010 DB - PRIME DP - Unbound Medicine ER -